RCMT reported revenue of
RCMT reported revenue of
About RCM
The statements contained in this release that are not purely historical are forward-looking statements within the Private Securities Litigation Reform Act of 1995. They are subject to various risks, uncertainties, and other factors that could cause the Company’s actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should,” “are confident” or similar expressions. In addition, statements that are not historical should also be considered forward-looking statements. These statements are based on assumptions that we have made in light of our experience in the industry, and our perceptions of historical trends, current conditions, expected future developments, and other factors we believe are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to demand for the Company’s services, expectations regarding our future revenues and other financial results, such as cash flows, our pipeline, and potential project wins, and our expectations for investment and growth in our business. Such statements are based on current expectations that involve several known and unknown risks, uncertainties, and other factors, which may cause actual events to be materially different from those expressed or implied by such forward-looking statements. Risk, uncertainties, and other factors may emerge from time to time that could cause the Company’s actual results to differ from those indicated by the forward-looking statements. Investors are directed to consider such risks, uncertainties, and other factors described in documents filed by the Company with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company assumes no obligation (and expressly disclaims any such obligation) to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.
Tables to Follow
Condensed Consolidated Statements of Operations (Unaudited) (In Thousands, Except Share and Per Share Amounts) | ||||||
| Thirteen Weeks Ended | ||||||
2026 | 2025 | |||||
| Revenue | ||||||
| Cost of services | 69,734 | 55,889 | ||||
| Gross profit | 24,082 | 22,277 | ||||
| Selling, general and administrative | 15,568 | 15,275 | ||||
| Depreciation and amortization of property and equipment | 558 | 401 | ||||
| Operating income | 7,956 | 6,601 | ||||
| Other expense, net | 736 | 929 | ||||
| Income before income taxes | 7,220 | 5,672 | ||||
| Income tax expense | 2,319 | 1,887 | ||||
| Net income | ||||||
| Diluted net earnings per share data | ||||||
| Diluted weighted average shares outstanding | 7,187,516 | 7,537,787 | ||||
| Twenty-Six Weeks Ended | ||||||
2026 | 2025 | |||||
| Revenue | ||||||
| Cost of services | 130,751 | 118,384 | ||||
| Gross profit | 46,103 | 44,255 | ||||
| Selling, general and administrative | 31,097 | 30,246 | ||||
| Depreciation and amortization of property and equipment | 1,132 | 825 | ||||
| Operating income | 13,894 | 13,184 | ||||
| Other expense, net | 1,298 | 1,627 | ||||
| Income before income taxes | 12,596 | 11,557 | ||||
| Income tax expense | 3,851 | 3,586 | ||||
| Net income | ||||||
| Diluted net earnings per share data | ||||||
| Diluted weighted average shares outstanding | 7,316,974 | 7,650,272 | ||||
Supplemental Operating Results on a Non-GAAP Basis
(Unaudited)
(In Thousands, Except Per Share Amounts)
The following non-GAAP measures, which adjust for the categories of expenses described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures (“Adjusted operating income,” “EBITDA,” “Adjusted EBITDA,” “Adjusted net income” and “Adjusted diluted net earnings per share”) are useful information for investors, shareholders, and other stakeholders of our Company in gauging our results of operations on an ongoing basis and to enhance investors’ overall understanding of our current financial performance and period-to-period comparisons. Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share should not be considered alternatives to operating income or net income, as the case may be, as an indicator of performance. In addition, Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share do not take into account changes in certain assets and liabilities and interest and income taxes that can affect cash flows. We do not intend the presentation of these non-GAAP measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP. These non-GAAP measures should be read-only in conjunction with our consolidated financial statements prepared in accordance with GAAP.
The following unaudited table presents the Company’s GAAP operating income and GAAP net income and the corresponding adjustments used to calculate Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share for the thirteen and twenty-six weeks ended
| Thirteen Weeks Ended | Twenty-Six Weeks Ended | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||
| GAAP operating income | ||||||||||||
| Adjustments | ||||||||||||
| Excess professional fees | - | - | 647 | - | ||||||||
| Equity compensation | 824 | 1,133 | 1,832 | 1,906 | ||||||||
| Adjusted operating income (non-GAAP) | ||||||||||||
| GAAP net income | ||||||||||||
| Income tax expense | 2,319 | 1,887 | 3,851 | 3,586 | ||||||||
| Interest expense, net | 744 | 650 | 1,370 | 1,301 | ||||||||
| Depreciation of property and equipment | 558 | 401 | 1,112 | 825 | ||||||||
| EBITDA (non-GAAP) | ||||||||||||
| Adjustments | ||||||||||||
| Excess professional fees | - | - | 647 | - | ||||||||
| (Gain) loss on foreign currency transactions | (8 | ) | 279 | (72 | ) | 326 | ||||||
| Equity compensation | 824 | 1,133 | 1,832 | 1,906 | ||||||||
| Adjusted EBITDA (non-GAAP) | ||||||||||||
Supplemental Operating Results on a Non-GAAP Basis (Continued) (Unaudited) (In Thousands) | ||||||||||||
| Thirteen Weeks Ended | Twenty-Six Weeks Ended | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||
| GAAP net income | ||||||||||||
| Adjustments | ||||||||||||
| Excess professional fees | - | - | 647 | - | ||||||||
| (Gain) loss on foreign currency transactions | (8 | ) | 279 | (72 | ) | 326 | ||||||
| Equity compensation | 824 | 1,133 | 1,832 | 1,906 | ||||||||
| Tax impact from normalized rate | 149 | (26 | ) | (200 | ) | (137 | ) | |||||
| Adjusted net income (non-GAAP) | ||||||||||||
| GAAP diluted net earnings per share | ||||||||||||
| Adjustments | ||||||||||||
| Excess professional fees | - | - | - | |||||||||
| (Gain) loss on foreign currency transactions | ( | ) | ||||||||||
| Equity compensation | ||||||||||||
| Tax impact from normalized rate(a) | - | ( | ) | ( | ) | |||||||
| Adjusted diluted net earnings per share (non-GAAP) | ||||||||||||
Summary of Selected Income Statement Data (Unaudited) (In Thousands) | ||||||||||||
| Thirteen Weeks Ended | ||||||||||||
| Specialty Health Care | Engineering | Life Sciences, Data and Solutions | Consolidated | |||||||||
| Revenue | ||||||||||||
| Cost of services | 31,566 | 32,484 | 5,684 | 69,734 | ||||||||
| Gross profit | ||||||||||||
| Gross profit margin | 29.4 | % | 17.8 | % | 40.6 | % | 25.7 | % | ||||
| Thirteen Weeks Ended | ||||||||||||
| Specialty Health Care | Engineering | Life Sciences, Data and Solutions | Consolidated | |||||||||
| Revenue | ||||||||||||
| Cost of services | 30,545 | 20,031 | 5,313 | 55,889 | ||||||||
| Gross profit | ||||||||||||
| Gross profit margin | 28.7 | % | 24.5 | % | 39.8 | % | 28.5 | % | ||||
| Twenty-Six Weeks Ended | ||||||||||||
| Specialty Health Care | Engineering | Life Sciences, Data and Solutions | Consolidated | |||||||||
| Revenue | ||||||||||||
| Cost of services | 66,229 | 53,320 | 11,202 | 130,751 | ||||||||
| Gross profit | ||||||||||||
| Gross profit margin | 28.7 | % | 18.8 | % | 39.0 | % | 26.1 | % | ||||
| Twenty-Six Weeks Ended | ||||||||||||
| Specialty Health Care | Engineering | Life Sciences, Data and Solutions | Consolidated | |||||||||
| Revenue | ||||||||||||
| Cost of services | 61,624 | 45,989 | 10,771 | 118,384 | ||||||||
| Gross profit | ||||||||||||
| Gross profit margin | 28.4 | % | 21.6 | % | 39.7 | % | 27.2 | % | ||||
Consolidated Balance Sheets (Unaudited) (In thousands, except share amounts) | ||||||||
| 2026 | 2026 | |||||||
| Current assets: | ||||||||
| Cash | ||||||||
| Accounts receivable and contract assets, net of provision for credit losses of | 81,479 | 81,243 | ||||||
| Transit accounts receivable | 6,614 | 8,017 | ||||||
| Prepaid expenses and other current assets | 5,682 | 7,704 | ||||||
| Total current assets | 100,360 | 99,886 | ||||||
| Property and equipment, net | 6,355 | 7,265 | ||||||
| Other assets: | ||||||||
| Deposits | 262 | 261 | ||||||
| Deferred tax assets, foreign | 6 | 6 | ||||||
| 22,147 | 22,147 | |||||||
| Operating right of use asset | 4,876 | 4,832 | ||||||
| Total other assets | 27,291 | 27,246 | ||||||
| Total assets | ||||||||
| Current liabilities: | |||||||||
| Accounts payable and accrued expenses | |||||||||
| Transit accounts payable | 14,459 | 16,247 | |||||||
| Accrued payroll and related costs | 12,881 | 10,784 | |||||||
| Finance lease payable | 750 | 843 | |||||||
| Income taxes payable | 352 | 391 | |||||||
| Operating lease liabilities | 1,142 | 1,209 | |||||||
| Deferred revenue | 8,204 | 14,761 | |||||||
| Total current liabilities | 52,183 | 53,884 | |||||||
| Deferred income taxes, net, domestic | 5,673 | 5,673 | |||||||
| Finance lease payable, net of current position | - | 380 | |||||||
| Operating lease liabilities, net of current position | 3,945 | 3,813 | |||||||
| Borrowings under revolving credit facility | 23,383 | 24,673 | |||||||
| Total liabilities | 85,184 | 88,423 | |||||||
| Contingencies (note 16) and Commitments (note 15) | |||||||||
| Stockholders’ equity: | |||||||||
| Preferred stock, | |||||||||
| no shares issued or outstanding | - | - | |||||||
| Common stock, | |||||||||
| 18,088,821 shares issued and 7,087,614 shares outstanding at shares outstanding at | 904 | 900 | |||||||
| Additional paid-in capital | 123,220 | 122,244 | |||||||
| Accumulated other comprehensive loss | (3,034 | ) | (2,814 | ) | |||||
| Retained earnings | 19,141 | 10,396 | |||||||
10,652,841 shares at | (91,409 | ) | (84,752 | ) | |||||
| Stockholders’ equity | 48,822 | 45,974 | |||||||
| Total liabilities and stockholders’ equity | |||||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) (In Thousands) | |||||||
| Thirteen Weeks Ended | |||||||
2026 | 2025 | ||||||
| Net income | |||||||
| Adjustments to reconcile net income to cash used in operating activities | 1,731 | 1,796 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable and contract assets | 3,612 | (15,322 | ) | ||||
| Prepaid expenses and other current assets | 1,443 | 1,253 | |||||
| Net of transit accounts receivable and payable | (143 | ) | 2,722 | ||||
| Accounts payable and accrued expenses | 4,242 | (4,739 | ) | ||||
| Accrued payroll and related costs | 615 | (2,236 | ) | ||||
| Operating lease liabilities | (349 | ) | (294 | ) | |||
| Income taxes payable | (27 | ) | 501 | ||||
| Deferred revenue | (5,152 | ) | 4,681 | ||||
| Deposits | (3 | ) | (25 | ) | |||
| Total adjustments | 5,969 | (11,663 | ) | ||||
| Net cash provided (used in) by operating activities | 10,870 | (7,878 | ) | ||||
| Net cash used in investing activities | (104 | ) | (473 | ) | |||
| Net cash (used in) provided by financing activities | (6,768 | ) | 8,491 | ||||
| Effect of exchange rate changes on cash | (34 | ) | 151 | ||||
| Increase in cash | |||||||
| Twenty-Six Weeks Ended | |||||||
2026 | 2025 | ||||||
| Net income | |||||||
| Adjustments to reconcile net income to cash used in operating activities | 3,594 | 3,255 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable and contract assets | (280 | ) | (5,764 | ) | |||
| Prepaid expenses and other current assets | 2,019 | 3,040 | |||||
| Net of transit accounts receivable and payable | (385 | ) | (1,671 | ) | |||
| Accounts payable and accrued expenses | 4,952 | (3,381 | ) | ||||
| Accrued payroll and related costs | 2,108 | 429 | |||||
| Operating lease liabilities | (623 | ) | (535 | ) | |||
| Income taxes payable | (36 | ) | 430 | ||||
| Deferred revenue | (6,553 | ) | 5,037 | ||||
| Deposits | (1 | ) | (29 | ) | |||
| Total adjustments | 4,795 | 811 | |||||
| Net cash provided by operating activities | 13,540 | 8,782 | |||||
| Net cash used in investing activities | (201 | ) | (900 | ) | |||
| Net cash used in financing activities | (9,272 | ) | (7,092 | ) | |||
| Effect of exchange rate changes on cash | (404 | ) | (47 | ) | |||
| Increase in cash | |||||||
| Tel: 856.356.4500 | Corporate Contacts: | |
| info@rcmt.com | ||
| www.rcmt.com | Executive Chairman | |
| Chief Financial Officer |
Source: